Compare Palantir Technologies Inc (PLTR) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Palantir Technologies Inc trades at $199.09 (market cap $466.48B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Palantir Technologies Inc is far larger — about 18.5× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| PLTR | RPRX | |
|---|---|---|
Market Cap | $466.48B | $25.27B |
Volume | 15,675,589 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $207.18 | $63.96 |
52-Week Low | $107.27 | $35.44 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $457.28B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $198.78, up 3.48% with strong bullish technical signals and consecutive earnings beats. The stock shows robust revenue growth from $1.9B in 2022 to $4.48B in 2025, with net income turning positive to $1.63B. Recent partnership with Armada for sovereign AI infrastructure and positive analyst coverage support momentum, though valuation ratios remain elevated.
Outlook remains positive with accelerating AI adoption and strong fundamentals, but high P/E of 165.91 and P/S of 81.08 present valuation risks. Analyst consensus price target of $185.58 suggests potential downside, while growth trajectory and institutional bullish sentiment offer upside potential amid competitive and execution risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
